Simi S M, Pruthvi R, Nagashree K S, Vishweshwaraiah Bhavya Malgur, Osmani Riyaz Ali M
Department of Pharmacology, JSS College of Pharmacy, Mysuru 570015, India.
JSS College of Pharmacy, Mysuru, JSS Academy of Higher Education & Research, Mysuru, 570 015, Karnataka, India.
Crit Rev Ther Drug Carrier Syst. 2025;42(5):101-120. doi: 10.1615/CritRevTherDrugCarrierSyst.2025053964.
Microneedle-based delivery systems have emerged as a groundbreaking technology in the realm of targeted cancer therapy. By facilitating the transdermal administration of therapeutic agents, microneedles offer a minimally invasive method to overcome the limitations posed by conventional drug delivery systems. This review comprehensively examines the potential of microneedles to enhance drug bioavailability, improve therapeutic outcomes, and reduce systemic toxicity. We explore the diverse applications of MNs in cancer treatment, including their use in chemotherapy, where MNs enable direct delivery of chemotherapeutic agents to tumor sites, thus maximizing drug efficacy and minimizing adverse effects. Additionally, we discuss the role of MNs in immunotherapy, highlighting how they can be used to deliver immune-modulating agents that activate localized immune responses against cancer cells. Furthermore, the potential of microneedles in gene therapy is addressed, emphasizing their ability to deliver genetic material directly to tumor cells, thereby offering a novel approach to cancer treatment. The review also delves into the challenges associated with MN-based therapies, such as ensuring consistent and controlled drug delivery, addressing patient variability, and overcoming manufacturing and scalability issues. Despite these challenges, the advancements in microneedle technology and the promising results from preclinical and clinical studies underscore their transformative potential in cancer therapy. We emphasize the need for further research and clinical trials to validate the efficacy and safety of microneedles.
基于微针的给药系统已成为靶向癌症治疗领域的一项突破性技术。通过促进治疗药物的经皮给药，微针提供了一种微创方法，以克服传统药物递送系统带来的局限性。本综述全面研究了微针在提高药物生物利用度、改善治疗效果和降低全身毒性方面的潜力。我们探讨了微针在癌症治疗中的多种应用，包括其在化疗中的应用，微针能够将化疗药物直接递送至肿瘤部位，从而使药物疗效最大化并将不良反应最小化。此外，我们讨论了微针在免疫治疗中的作用，强调了它们如何用于递送激活针对癌细胞的局部免疫反应的免疫调节药物。此外，还探讨了微针在基因治疗中的潜力，强调了它们将遗传物质直接递送至肿瘤细胞的能力，从而为癌症治疗提供了一种新方法。该综述还深入探讨了基于微针疗法相关的挑战，例如确保持续且可控的药物递送、应对患者个体差异以及克服制造和可扩展性问题。尽管存在这些挑战，但微针技术的进步以及临床前和临床研究取得的令人鼓舞的结果凸显了它们在癌症治疗中的变革潜力。我们强调需要进一步的研究和临床试验来验证微针的疗效和安全性。
